UroGen Pharma (URGN) Cash from Financing Activities (2018 - 2026)

UroGen Pharma's Cash from Financing Activities history runs 9 years deep, the most recent figure standing at $65.2 million for Q1 2026.

• Quarterly Cash from Financing Activities rose 191676.47% year-over-year to $65.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $105.1 million (down 24.93% YoY) and the FY2025 annual result came in at $39.9 million, down 79.49% from the prior year.
• Cash from Financing Activities was $65.2 million for Q1 2026 at UroGen Pharma, up from $31.3 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $116.1 million in Q3 2023 and bottomed at -$77000.0 in Q2 2022.
• A 5-year average of $30.2 million and a median of $8.3 million in 2025 frame the typical range for Cash from Financing Activities.
• Peak annual rise in Cash from Financing Activities reached 1768450.0% in 2022, while the deepest fall reached 100.11% in 2022.
• UroGen Pharma's Cash from Financing Activities stood at $25.4 million in 2022, then plunged by 99.84% to $40000.0 in 2023, then jumped by 77.5% to $71000.0 in 2024, then jumped by 44007.04% to $31.3 million in 2025, then jumped by 108.21% to $65.2 million in 2026.
• Business Quant data shows URGN's Cash from Financing Activities at $65.2 million in Q1 2026, $31.3 million in Q4 2025, and $8.3 million in Q3 2025.